Ardelyx Inc (ARDX) Stock
Key stats
- Market cap
- $786.80M
- Price / Earnings ratio
- -13.6x
- EPS (TTM)
- -$0.23
- Volume
- Loading
- 52-week high
- $8.40
- 52-week low
- $2.80
Source: third-party data provider, as of November 13, 2026
Compare with ARDX
Recent news
What Ardelyx (ARDX) Said on Its Q3 Earnings Call
What Ardelyx (ARDX) Said on Its Q3 Earnings Call
ARDX
Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
ARDX
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
ARDX
New Strong Sell Stocks for October 9th
New Strong Sell Stocks for October 9th
ARDXNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 49.16
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.02
- SMA 50
- $3.30
- Price below SMA 50
- EMA 50
- $3.38
- Price below EMA 50
- SMA 200
- $5.15
- Price below SMA 200
- EMA 200
- $4.85
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.06 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
What Ardelyx (ARDX) Said on Its Q3 Earnings Call
What Ardelyx (ARDX) Said on Its Q3 Earnings Call
ARDXArdelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
ARDXArdelyx (ARDX) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
ARDXNew Strong Sell Stocks for October 9th
New Strong Sell Stocks for October 9th
ARDX
New Strong Sell Stocks for October 7th
New Strong Sell Stocks for October 7th
ARDX
Robbins LLP Urges ARDX Stockholders Who Lost Money Investing in Ardelyx, Inc. to Contact the Firm for Information About Leading the Class Action
Robbins LLP Urges ARDX Stockholders Who Lost Money Investing in Ardelyx, Inc. to Contact the Firm for Information About Leading the Class Action
ARDX
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
ARDX
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX
ARDX
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
ARDX
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
ARDXNews tone: automated (AI) classification of the article's content, not a price prediction.
About Ardelyx Inc
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael G. Raab | President, CEO & Director | 1965 |
| Ms. Sue Hohenleitner | Chief Financial Officer | 1971 |
| Dr. John Bishop Ph.D. | Chief Technical & Quality Officer | 1962 |
| Mr. Joseph Reilly | Senior VP of Finance & Principal Accounting Officer | 1974 |
| Ms. Lisa M. Caperelli | Senior Vice President of Investor Relations and Corporate Communications | — |
| Ms. Felecia W. Ettenberg | Chief Legal Officer | 1971 |
| Mr. James P. Brady | Chief Human Resources Officer | 1971 |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Patient Officer Emeritus | 1963 |
| Mr. Mike Kelliher | Chief Business Officer | 1977 |
| Dr. Rajani Dinavahi M.D. | Chief Medical Officer | 1976 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 49.16
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.02
- SMA 50
- $3.30
- Price below SMA 50
- EMA 50
- $3.38
- Price below EMA 50
- SMA 200
- $5.15
- Price below SMA 200
- EMA 200
- $4.85
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $9.00
- Average
- $11.67
- High
- $15.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.8 | -10.6 | ||||||||||
| 2022 | -29.7 | -8.3 | +46.6 | -23.4 | -21.4 | -4.8 | +18.6 | +41.8 | +21.4 | +11.9 | +9.6 | +62.9 |
| 2023 | +9.3 | -4.3 | +64.0 | -5.5 | -28.2 | -3.1 | +19.4 | +10.9 | -15.4 | -2.7 | +14.5 | +30.3 |
| 2024 | +44.3 | +0.3 | -21.8 | -13.6 | +3.8 | +7.1 | -26.7 | +12.4 | +22.4 | -14.3 | -6.9 | -8.5 |
| 2025 | +4.7 | +1.3 | -3.3 | +15.0 | -32.9 | +1.8 | +8.7 | +46.9 | -13.9 | +13.1 | -2.0 | +4.3 |
| 2026 | +25.0 | -15.9 | -7.4 | +3.6 | -12.2 | -11.0 | -4.1 | -24.1 | -9.0 | -10.4 | +3.3 |
